Colon cancer cells use mysterious RNA strands to avoid cell death

May 16, 2018, Case Western Reserve University
A hairpin loop from a pre-mRNA. Highlighted are the nucleobases (green) and the ribose-phosphate backbone (blue). Note that this is a single strand of RNA that folds back upon itself. Credit: Vossman/ Wikipedia

Researchers from Case Western Reserve University School of Medicine have discovered how unusually long strands of RNA help colon cancer cells avoid death, allowing unregulated growth. Unlike other RNAs, the intriguing strands do not appear to encode proteins and are termed "long non-coding RNAs" or "lincRNAs."A new study showed some lincRNAs could be targeted by drug developers to halt colon cancer.

In a new study published in Scientific Reports, researchers compared lincRNA levels inside tumor , to levels inside healthy colon cells. They found over 200 lincRNAs at significantly different levels inside the tumor cells as compared to normal cells. One in particular, called lincDUSP, was overexpressed in 91 percent of the tumor samples. A few tumors had more than fifteen times the normal amount of lincDUSP. The significant increase suggested this mysterious, and previously uncharacterized, RNA could be cancer-causing.

"To determine whether lincDUSP shows oncogenic activity in colon cancer, we decided to test the effects of depleting lincDUSP in patient-derived colon cell lines," wrote the authors. The researchers genetically modified to deplete lincDUSP, and surprisingly, the cells began replicating at normal rates. They no longer had unrestricted growth associated with colon cancer . Small molecules that inhibit lincDUSP, say the researchers, could have similar effects.

"Our work demonstrates that not only protein-coding genes but also non-coding genes contribute to colon cancer progression," says Ahmad Khalil, Ph.D., senior author, assistant professor of genetics and genome sciences at Case Western Reserve University School of Medicine, and member of the Case Comprehensive Cancer Center. "LincRNAs could be exploited as direct drug targets in this and other human diseases."

Khalil's team discovered that depleting lincDUSP restored inherent cell death mechanisms. Colon cancer cells with low levels of lincDUSP became susceptible to cellular checkpoints that keep growth in check. They immediately committed cell suicide—apoptosis—at the first sign of DNA damage. Depleting the single lincRNA also had widespread genetic effects. Khalil's team discovered that reducing lincDUSP levels affected expression of over 800 other genes. These results, combined with the team's experiments showing lincDUSP interacting with DNA, add to a growing body of evidence that lincRNAs are central to gene regulation. As such, they could represent an intriguing arena for drug developers.

"Not much is known about the role of long non-coding RNAs in ," says Khalil. "Using new technologies that target RNA molecules, instead of proteins, adds a new dimension to therapies."

Explore further: Cell type switch helps colon cancer evade treatment, study suggests

More information: Megan E. Forrest et al, Colon Cancer-Upregulated Long Non-Coding RNA lincDUSP Regulates Cell Cycle Genes and Potentiates Resistance to Apoptosis, Scientific Reports (2018). DOI: 10.1038/s41598-018-25530-5

Related Stories

Cell type switch helps colon cancer evade treatment, study suggests

May 16, 2018
Researchers in Germany have discovered that colon cancers are often resistant to existing drug treatments because they are composed of two different cell types that can replace each other when one cell type is killed. The ...

New study offers novel treatment strategy for patients with colon cancer

September 20, 2017
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide.

Researchers restore drug sensitivity in breast cancer tumors

August 11, 2016
A team of Case Western Reserve University School of Medicine cancer researchers has uncovered one way certain tumors resist vital medication.

Researchers find new trigger for onset of colon cancer, which may lead to better therapies

April 2, 2018
Colon cancer is the second most common cause of cancer-related deaths. The APC protein has long been known for its critical role in preventing colorectal cancer. When APC is inactivated, the development of colorectal cancer ...

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

Scientists discover a genetic mechanism for cancer progression

September 11, 2015
Genetics researchers from Case Western Reserve School of Medicine have identified a novel long non-coding RNA (lncRNA), dubbed DACOR1, that has the potential to stymie the growth of tumor cells in the second-most deadly form ...

Recommended for you

New drug candidate makes cancer cells more sensitive to radiotherapy

September 26, 2018
Researchers from Karolinska Institutet and Kancera AB have developed a molecule that makes cancer cells sensitive to radiotherapy. In a study published in Nature Communications, the researchers describe a new way to block ...

Aspirin could play valuable role as additional treatment for cancer

September 26, 2018
Regular use of aspirin could help in the treatment of some cancers, finds a new review of 71 medical studies.

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.